Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of $1.08, $0.41 better than the analyst estimate of $0.67. Revenue for the quarter came in at $26.2 million versus the consensus estimate of $15.92 million.

2025 Financial Guidance:

Operating Expenses (excluding share-based compensation): The Company continues to expect full year 2025 R&D expenses of $32 million to $38 million and SG&A expenses of $50 million to $60 million, in each case excluding share-based compensation.

Share-Based Compensation: The Company continues to expect full year share-based compensation expenses of $18 million to $20 million.

Non-GAAP Net Income (Loss) from Operations and Cash Burn4: The Company continues to expect 2025 levels of Non-GAAP Net Income (Loss) from Operations and Cash Burn in 2025 to be similar to levels incurred in 2024. Both Non-GAAP Net Income (Loss) from Operations and Cash Burn guidance metrics exclude one-time, non-recurring Revenue and Income items incurred throughout 2025.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.